Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Jim Bishop who wrote (94808)	10/25/2001 10:11:42 PM
From: Taki	Read Replies (1) \| Respond to of 150070

DNAP, UPDATE.THE POSTER WAS AT THE OPENING CC. READ HIS POSTS ON THE LINK BELOW. I WONDER WHERE THIS WILL GO.I ONLY HAVE 10K SHARES. hopeful107 $$$$ Reply To: None Thursday, 25 Oct 2001 at 8:32 PM EDT Post # of 130974 Frudakis's Talk at GSAC I just got into my hotel room at GSAC. Here's Frudakis's abstract. Complex Pharmacogenomics Data Resources and Algorithms Applied to Develop Accurate Drug-Patient Classification Tests Tony Frudakis, Matt Thomas, Zach Gaskin, Kondagunta Ventakeswarlu, Ponnuswamy Kolathupalayam Nachimuthu, DNAPrint Genomics, Inc., Sarasota, FL. DNAprint genomics, Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics to develop complex, quantitative drug-patient classification products for next generation's personalized medicine. We have used a vertical resequencing procedure with proprietary software tools to assemble a collection of highly detailed SNP and haplotype maps for various genes involved in xenobiotic disposition. Looking at 50 gene promoter, exon and 3'UTR in unrelated individuals of the major ethnic groups (nPO), we are finding an average of 25 SNPs per gene (1 SNP per 280 bases). Results to date show that the number of SNPs differ dramatically from gene to gene, as well as from region to region within any particular gene. We will discuss polymorphism validation rates or our SNPS , as well as for candidate SNPs culled from public data resources, and present methods we have devised that ameliorate the "discovery" of monomorphic false positives. The primary effort in our laboratory focuses on the development of analytical algorithms capable of drawing quantitative relationships between haplotypes and continuously distributed drug reaction phenotypes. To generate training sets for our artificial intelligence algorithms, we have completed a genotyping/haplotyping study of a common trait that serves as a pliable model for these types of phenotypes. Our results validate both the candidate gene approach, and our algorithmic approach for "solving" complex human traits through systematic haplotype analyses. We have found 25 SNPs in 3 different genes to be individually associated with one particular human trait value. As discrete markers, or even in various combinations, the SNPs tend to explain a relatively low percent of the phenotypic variation for this trait but at the level of the haplotype, the SNPs combine to greater than 95%. Results from other projects that explain variability in drug-induced hepatocellular toxicity,, myalgia and variable response for a variety of FDA approved drugs will be presented, and algorithmic methods for "mining" genetic data sets for predictive value will be discussed. I don't know if anyone else had posted this info yet. dnastuff2 Scientist II ragingbull.lycos.com